FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175263573> ?p ?o ?g. }

• W3175263573 endingPage "P" @default.
• W3175263573 startingPage "716" @default.
• W3175263573 abstract "Many of those with T1D in the US use MDI as their insulin delivery method. Hybrid closed-loop (HCL) systems such as the Omnipod 5 System may improve glycemic outcomes and reduce treatment burden, however, these systems must be accessible to current MDI users. We performed a subgroup analysis of participants transitioning directly from MDI in the pivotal study of the Omnipod 5 System. Children (6-13.9 y) and adults (14-70 y) with T1D≥6 months and A1C<10% used the HCL system for 3 months at home, after a 14-d run-in phase of MDI as their standard therapy (ST). Primary efficacy endpoints were change in A1C and percent time with sensor glucose in target range (TIR, 70-180 mg/dL) during HCL compared with MDI. Thirteen children (mean±SD, age 11±2 y, T1D duration 4±2 y, A1C 7.7±1.0%, 77% CGM users) and 23 adults (age 38±13 y, T1D duration 16±12 y, A1C 7.4±0.9%, 91% CGM users) used MDI as ST. HCL use among children and adults improved TIR by 16.7±14.0% and 12.7±12.5%, and reduced A1C by 1.0±0.8% and 0.5±0.7%, respectively, compared with MDI (all p<0.05, Table). There were no episodes of severe hypoglycemia or diabetic ketoacidosis in this subgroup. Direct transition from MDI to the Omnipod 5 System is feasible and effective in reducing A1C and improving TIR in T1D. Most participants (97%) chose to continue HCL use during an extension phase, suggesting high acceptability of the system among MDI users.View largeDownload slideView largeDownload slide DisclosureV. Shah: Advisory Panel; Self; Medscape, Sanofi, Research Support; Self; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk, Sanofi, vTv Therapeutics. L. M. Laffel: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompe, Insulogic LLC, Janssen Pharmaceuticals, Inc., Laxmi Therapeutic Devices, LifeScan, Lilly Diabetes, Medtronic, Provention Bio, Inc. G. Aleppo: Consultant; Self; Dexcom, Inc., Insulet Corporation, Research Support; Self; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk. B. A. Buckingham: Advisory Panel; Self; Medtronic, Tolerion, Inc., Research Support; Self; Beta Bionics, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. D. Desalvo: Consultant; Self; Insulet Corporation, Research Support; Self; Insulet Corporation, Speaker’s Bureau; Self; Dexcom, Inc. I. B. Hirsch: Consultant; Self; Abbott Diabetes, Bigfoot Biomedical, Inc., Research Support; Self; Insulet Corporation, Leona M. and Harry B. Helmsley Charitable Trust, Medtronic. S. A. Macleish: Advisory Panel; Self; Insulet Corporation. J. E. Pinsker: Advisory Panel; Self; Medtronic, Consultant; Self; Eli Lilly and Company, Tandem Diabetes Care, Research Support; Self; Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. T. T. Ly: Employee; Self; Insulet Corporation. A. B. Criego: Consultant; Self; Bigfoot Biomedical, Inc., Other Relationship; Self; Sanofi, Research Support; Self; Abbott Diabetes, Eli Lilly and Company, Insulet Corporation, Medtronic. A. L. Carlson: Board Member; Self; JDRF, Other Relationship; Self; Medtronic, Research Support; Self; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Novo Nordisk, Omnipod, Sanofi, UnitedHealth Group. A. Bhargava: Research Support; Self; Abbott, AbbVie Inc., Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Covance Inc., Dexcom, Inc., Eli Lilly and Company, Gan & Lee Pharmaceuticals, Gan & Lee Pharmaceuticals, Insulet Corporation, Janssen Research & Development, LLC, Madrigal Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Mylan N. V., Novo Nordisk, Quintiles, Sanofi, Senseonics, Senseonics, Tolerion, Inc., viking. B. W. Bode: Advisory Panel; Self; Eli Lilly and Company, Consultant; Self; Bigfoot Biomedical, Inc., Companion Medical, Lexicon Pharmaceuticals, Inc., Medtronic, Novo Nordisk Inc., Zealand Pharma A/S, Research Support; Self; Abvance Therapeutics, Dexcom, Inc., Diasome Pharmaceuticals, Inc., Dompe, Eli Lilly and Company, Eyenuk, Inc., Insulet Corporation, Jaeb Center for Health Research, Medtronic, Nova Biomedical, Novo Nordisk, Provention Bio, Inc., REMD Biotherapeutics, Sanofi, Senseonics, Viacyte, Inc., vTv Therapeutics, Xeris Pharmaceuticals, Inc., Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, MannKind Corporation, Medtronic, Novo Nordisk, Sanofi, Stock/Shareholder; Self; AgaMatrix, Aseko, Inc., Glytec, LLC. S. A. Brown: Research Support; Self; Dexcom, Inc., Insulet Corporation, Roche Diabetes Care, Tandem Diabetes Care, Tolerion, Inc.FundingInsulet Corporation" @default.
• W3175263573 created "2021-07-05" @default.
• W3175263573 creator A5004275841 @default.
• W3175263573 creator A5005036709 @default.
• W3175263573 creator A5007119846 @default.
• W3175263573 creator A5007320108 @default.
• W3175263573 creator A5014150950 @default.
• W3175263573 creator A5021011617 @default.
• W3175263573 creator A5023814642 @default.
• W3175263573 creator A5028301400 @default.
• W3175263573 creator A5028530813 @default.
• W3175263573 creator A5029280234 @default.
• W3175263573 creator A5057738176 @default.
• W3175263573 creator A5058966489 @default.
• W3175263573 creator A5062084555 @default.
• W3175263573 creator A5066449312 @default.
• W3175263573 creator A5067199927 @default.
• W3175263573 creator A5067942725 @default.
• W3175263573 creator A5068269802 @default.
• W3175263573 date "2021-06-01" @default.
• W3175263573 modified "2023-10-06" @default.
• W3175263573 title "716-P: Transition from Multiple Daily Injections (MDI) to Omnipod 5 Automated Insulin Delivery System Improves A1C in Type 1 Diabetes (T1D)" @default.
• W3175263573 doi "https://doi.org/10.2337/db21-716-p" @default.
• W3175263573 hasPublicationYear "2021" @default.
• W3175263573 type Work @default.
• W3175263573 sameAs 3175263573 @default.
• W3175263573 citedByCount "1" @default.
• W3175263573 countsByYear W31752635732021 @default.
• W3175263573 crossrefType "journal-article" @default.
• W3175263573 hasAuthorship W3175263573A5004275841 @default.
• W3175263573 hasAuthorship W3175263573A5005036709 @default.
• W3175263573 hasAuthorship W3175263573A5007119846 @default.
• W3175263573 hasAuthorship W3175263573A5007320108 @default.
• W3175263573 hasAuthorship W3175263573A5014150950 @default.
• W3175263573 hasAuthorship W3175263573A5021011617 @default.
• W3175263573 hasAuthorship W3175263573A5023814642 @default.
• W3175263573 hasAuthorship W3175263573A5028301400 @default.
• W3175263573 hasAuthorship W3175263573A5028530813 @default.
• W3175263573 hasAuthorship W3175263573A5029280234 @default.
• W3175263573 hasAuthorship W3175263573A5057738176 @default.
• W3175263573 hasAuthorship W3175263573A5058966489 @default.
• W3175263573 hasAuthorship W3175263573A5062084555 @default.
• W3175263573 hasAuthorship W3175263573A5066449312 @default.
• W3175263573 hasAuthorship W3175263573A5067199927 @default.
• W3175263573 hasAuthorship W3175263573A5067942725 @default.
• W3175263573 hasAuthorship W3175263573A5068269802 @default.
• W3175263573 hasConcept C126322002 @default.
• W3175263573 hasConcept C134018914 @default.
• W3175263573 hasConcept C187212893 @default.
• W3175263573 hasConcept C2779306644 @default.
• W3175263573 hasConcept C2780473172 @default.
• W3175263573 hasConcept C2780668416 @default.
• W3175263573 hasConcept C2781232474 @default.
• W3175263573 hasConcept C2781283889 @default.
• W3175263573 hasConcept C2994527087 @default.
• W3175263573 hasConcept C555293320 @default.
• W3175263573 hasConcept C71924100 @default.
• W3175263573 hasConceptScore W3175263573C126322002 @default.
• W3175263573 hasConceptScore W3175263573C134018914 @default.
• W3175263573 hasConceptScore W3175263573C187212893 @default.
• W3175263573 hasConceptScore W3175263573C2779306644 @default.
• W3175263573 hasConceptScore W3175263573C2780473172 @default.
• W3175263573 hasConceptScore W3175263573C2780668416 @default.
• W3175263573 hasConceptScore W3175263573C2781232474 @default.
• W3175263573 hasConceptScore W3175263573C2781283889 @default.
• W3175263573 hasConceptScore W3175263573C2994527087 @default.
• W3175263573 hasConceptScore W3175263573C555293320 @default.
• W3175263573 hasConceptScore W3175263573C71924100 @default.
• W3175263573 hasIssue "Supplement 1" @default.
• W3175263573 hasLocation W31752635731 @default.
• W3175263573 hasOpenAccess W3175263573 @default.
• W3175263573 hasPrimaryLocation W31752635731 @default.
• W3175263573 hasRelatedWork W1971680228 @default.
• W3175263573 hasRelatedWork W2000571139 @default.
• W3175263573 hasRelatedWork W2017030704 @default.
• W3175263573 hasRelatedWork W2043682428 @default.
• W3175263573 hasRelatedWork W2353582818 @default.
• W3175263573 hasRelatedWork W2585489026 @default.
• W3175263573 hasRelatedWork W2768324963 @default.
• W3175263573 hasRelatedWork W3160733408 @default.
• W3175263573 hasRelatedWork W3214191526 @default.
• W3175263573 hasRelatedWork W4281713367 @default.
• W3175263573 hasVolume "70" @default.
• W3175263573 isParatext "false" @default.
• W3175263573 isRetracted "false" @default.
• W3175263573 magId "3175263573" @default.
• W3175263573 workType "article" @default.